- Home
- NAMM vs KLRS Comparison
NAMM vs KLRS Comparison
Compare NAMM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAMM | KLRS |
|---|---|---|
| Founded | 2024 | 2019 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 46.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAMM | KLRS |
|---|---|---|
| Price | $1.04 | $8.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 151.4K | ★ 174.7K |
| Earning Date | 04-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,348,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $109.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $0.96 | $2.14 |
| 52 Week High | $55.00 | $12.90 |
Technical Indicators
Market Signals| Indicator | NAMM | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.99 |
| Support Level | N/A | $9.00 |
| Resistance Level | N/A | $9.45 |
| Average True Range (ATR) | 0.00 | 1.15 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 0.00 | 23.56 |
Price Performance
Historical ComparisonAbout NAMM Namib Minerals Ordinary Shares
Namib Minerals is a gold producer, developer and explorer with operations focused in Zimbabwe.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.